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Objectives The purpose of this analysis was to characterize the progression of coronary atherosclerosis in patients with con-
comitant peripheral arterial disease (PAD).
Background Peripheral arterial disease is associated with adverse cardiovascular outcomes. The impact of concomitant PAD
on coronary atherosclerosis progression in patients with coronary artery disease has not been well established.
Methods The burden and progression of coronary atherosclerosis was investigated in 3,479 patients with coronary artery
disease with (n  216) and without (n  3,263) concomitant PAD who participated in 7 clinical trials that em-
ployed serial intravascular ultrasound imaging.
Results Patients with PAD had a greater percent atheroma volume (40.4  9.2% vs. 38.5  9.1%, p  0.002) and per-
centage of images containing calcium (35.1  26.2% vs. 29.6  24.2%, p  0.002), in association with smaller
lumen volume (275.7  101.6 mm3 vs. 301.4  110.3 mm3, p  0.001) and vessel wall volume (467.7 
166.8 mm3 vs. 492.9  169.8 mm3, p  0.01). On serial evaluation, patients with PAD demonstrated greater
progression of percent atheroma volume (0.58  0.38 vs. 0.23  0.3%, p  0.009) and total atheroma vol-
ume (0.17  2.69 mm3 vs. 2.05  2.15 mm3, p  0.03) and experienced more cardiovascular events
(26.3% vs. 19.8%, p  0.03). In patients with PAD and without PAD, respectively, achieving levels of low-density
lipoprotein cholesterol 70 mg/dl was associated with less progression of percent atheroma volume (0.16 
0.27% vs. 0.76  0.20%, p  0.04; and 0.05  0.14% vs. 0.29  0.13%, p  0.001) and total atheroma
volume (3.0  1.9 mm3 vs. 1.0  1.4 mm3, p  0.04; and 3.3  1.1 mm3 vs. 1.6  1.0 mm3, p  0.001).
Conclusions Patients with concomitant PAD harbor more extensive and calcified coronary atherosclerosis, constrictive arterial
remodeling, and greater disease progression. These changes are likely to contribute to adverse cardiovascular
outcomes. The benefit for all patients achieving low levels of low-density lipoprotein cholesterol supports the
need for intensive lipid lowering in patients with PAD. (J Am Coll Cardiol 2011;57:1220–5) © 2011 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.10.034t
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SThe adverse cardiovascular outcomes observed among patients
with peripheral arterial disease (PAD) (1–3) highlight the need
for intensive risk factor modification (4). However, only
ne-quarter of PAD patients receive guideline-recommended
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accepted October 28, 2010.herapies (5). Most of these clinical events are attributed to the
oronary vasculature (1–3), regardless of whether a diagnosis of
oronary artery disease (CAD) is already established (6). While
he underlying mechanisms remain incompletely understood,
t is unknown whether coronary disease progression is different
n the setting of concomitant PAD.
Intravascular ultrasound (IVUS) has been increasingly
mployed in clinical trials and has enabled investigation of
he clinical factors associated with disease progression.
ccordingly, the objective of the current analysis was to
ssess the impact of an established clinical diagnosis of PAD
n the burden and progression of coronary atherosclerosis.
ethods
tudy population. This analysis included 3,479 CAD
atients who underwent serial IVUS examinations in 7
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March 8, 2011:1220–5 PAD and Coronary Atherosclerosisclinical trials (7–13). PAD was determined on the basis of 1)
symptoms of intermittent claudication with a documented low
ankle-brachial index (0.9); 2) obstructive disease on femoral
ngiography; or 3) a history of arterial revascularization within
he lower limbs. Each of the trials was approved by the
nstitutional review board at the participating sites, and all
atients provided informed written consent before enrollment.
VUS imaging. The details on IVUS image acquisition
nd analysis have been previously reported in detail (7–13).
he percent atheroma volume (PAV), total atheroma vol-
me (TAV), and volumes occupied by lumen and external
lastic membrane were calculated (14). Substantial plaque
rogression and regression were defined as at least a 5%
elative increase or decrease in PAV, respectively.
tatistical analysis. Patients were stratified according to
he presence (n  216) or absence (n  3263) of PAD.
esults are presented as percentages for categorical variables
nd mean  SD for continuous variables. When variables
ere not normally distributed, their results are expressed as
edian (interquartile range). Clinical and plaque character-
stics were compared by the Student t test or analysis of
ariance for continuous variables as appropriate. For cate-
orical variables, the chi-square test or Fisher’s exact test
as used. Changes in measures of risk factors, atheroma
urden, and vascular dimensions were compared by analysis
f covariance, after controlling for baseline values, and
xpressed as least squared mean  SE. In a secondary
nalysis, which aimed to assess the potential independent
ssociation of PAD with CAD progression, a propensity
nalysis was performed, in which every PAD patient was
atched to non-PAD patients in a 1:3 ratio on the basis of
he predicted probability for PAD. The propensity match-
Figure 1 Disease Progression in PAD Patients
Changes in (A) percent atheroma volume (PAV) and (B) total atheroma volume (TA
according to the presence or absence of peripheral arterial disease (PAD).ng process accounted for base-
ine characteristics including age,
ex, race, current smoking status,
ody mass index, hypertension,
iabetes mellitus, hyperlipid-
mia, heart failure, baseline risk
actor control, medications use (as-
irin, beta-blockers, angiotensin-
onverting enzyme inhibitor,
tatins, oral antidiabetic, study
edications), history of stroke,
nd myocardial infarction. A
-sided p value 0.05 was con-
idered statistically significant.
ll statistical analyses were performed with SAS version
.1 (SAS Institute, Cary, North Carolina).
esults
atient characteristics. Clinical characteristics of patients
ith PAD and without PAD are summarized in Table 1.
he PAD patients were older (p 0.001), more likely to be
mokers (p  0.001), and had more diabetes (p  0.001),
yperlipidemia (p  0.001) and heart failure (p  0.001).
here was no difference between the groups with regard to
se of cardioprotective therapies at baseline. Fewer patients
ith PAD were treated with a statin (p  0.01). Risk factor
ontrol at baseline and during the course of the studies is
ummarized in Table 2. PAD patients were more likely to
xperience a cardiovascular event (death/myocardial infarc-
ion/revascularization/stroke: 26.3% vs. 19.8%, p  0.03).
d percent of patients with (C) disease progression and (D) regression,
Abbreviations
and Acronyms
CAD  coronary artery
disease
IVUS  intravascular
ultrasound
PAD  peripheral arterial
disease
PAV  percent atheroma
volume
TAV  total atheroma
volumeV), an
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PAD and Coronary Atherosclerosis March 8, 2011:1220–5Clinical Characteristics and Medication Use of Patients With and Without PADTable 1 Clinical Characteristics and Medication Use of Patients With and Without PAD
Parameter
Non-PAD
(n  3,263, 93.8%)
PAD
(n  216, 6.2%) p Value
Age, yrs 57.6 9.4 61.0 9.0 0.001
Sex, female 28.9 34.7 0.07
Caucasian 92.2 88.9 0.08
African American 4.7 7.4 0.08
Current smoker 20.7 32.8 0.001
Body mass index, kg/m2 31.4 5.9 32.0 6.1 0.12
Hypertension 78.9 84.3 0.06
Diabetes mellitus 30.4 42.6 0.001
Hyperlipidemia 74.6 85.2 0.001
Angina 52.2 58.5 0.08
Heart failure 3.0 9.7 0.001
History of myocardial infarction 29.9 31.0 0.73
Stroke 0.4 0.9 0.24
History of percutaneous coronary intervention 43.8 46.3 0.49
History of coronary artery bypass grafting 3.1 3.9 0.51
Baseline medication use
Statin 75.8 72.2 0.23
Beta-blocker 74.3 73.6 0.83
Aspirin 93.5 90.7 0.12
ACE inhibitor 49.1 47.7 0.69
Calcium-channel blocker 32.5 35.6 0.34
Concomitant medication use
Statin 94.8 90.7 0.01
Beta-blocker 76.3 79.2 0.34
Aspirin 94.4 92.6 0.28
ACE inhibitor 54.9 55.1 0.97
Calcium-channel blocker 37.9 42.6 0.17
Treatment for REVERSAL (n  502) 0.80
40 mg pravastatin 228/458 (49.8) 21/44 (47.7)
80 mg atorvastatin 230/458 (50.2) 23/44 (52.3)
Treatment for CAMELOT (n  274) 0.98
Placebo 87/252 (34.5) 8/22 (36.4)
Amlodipine 84/252 (33.3) 7/22 (31.8)
Enalapril 81/252 (32.1) 7/22 (31.8)
Treatment for ACTIVATE (n  408) 0.72
Placebo 190/382 (49.7) 12/26 (46.2)
Pactimibe 192/382 (50.3) 14/26 (53.8)
Treatment for ASTEROID (n  349) N/A
Rosuvastatin 338/338 (100.0) 11/11 (100.0)
Treatment for ILLUSTRATE (n  910) 0.93
Atorvastatin 436/890 (49.0) 10/20 (50.0)
Torcetrapib/atorvastatin 454/890 (51.0) 10/20 (50.0)
Treatment for PERISCOPE (n  360) 0.10
Glimepiride 156/320 (48.8) 25/40 (62.5)
Pioglitazone 164/320 (51.3) 15/40 (37.5)
Treatment for STRADIVARIUS (n  676) 0.35
Placebo 311/623 (49.9) 30/53 (56.6)
Rimonabant 20 mg 312/623 (50.1) 23/53 (43.4)
Values are % or n/N (%).
ACE  angiotensin-converting enzyme; ACTIVATE  ACAT IntraVascular Atherosclerosis Treatment Evaluation; ASTEROID  A Study to Evaluate
the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden; CAMELOT Comparison of Amlodipine versus Enalapril
to Limit Occurrences of Thrombosis Intravascular Ultrasound; ILLUSTRATE Investigation of Lipid Level Management Using Coronary Ultrasound to
Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation; PERISCOPE  Pioglitazone Effect on Regression of Intravascular
Sonographic Coronary Obstruction Prospective Evaluation; REVERSAL Reversal of Atherosclerosis with Aggressive Lipid Lowering; STRADIVARIUS
Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant–the Intravascular Ultrasound Study.
P
t
0
2
w
d
1223JACC Vol. 57, No. 10, 2011 Hussein et al.
March 8, 2011:1220–5 PAD and Coronary AtherosclerosisAtherosclerosis burden and progression. Atheroma bur-
den and vascular dimensions at baseline and their serial
change are summarized in Table 3 and Figure 1. At
baseline, a greater PAV (p  0.002) and smaller lumen
volume (p  0.001) and external elastic membrane volume
(p  0.01) were observed in PAD patients. No differences
in TAV were observed between the groups (p  0.83). A
greater percentage of images containing calcium was ob-
served in PAD patients (p  0.002). While the smaller
vessel wall volumes in PAD patients suggests a greater
propensity to constrictive remodeling throughout the length
Measures of Risk Factor Control in PatientsWith and Without PADTable 2 Measures f Risk Factor Control in PatientsWith and Without PAD
Parameter
Non-PAD
(n  3,263)
PAD
(n  216) p Value
Low-density lipoprotein
cholesterol
Baseline, mg/dl 103.2 36.2 106.6 40.5 0.29
Follow-up, mg/dl 86.7 27.0 88.6 27.7 0.40
Percent change 9.1 5.9 9.7 6.0 0.71
High-density lipoprotein
cholesterol
Baseline, mg/dl 42.5 11.7 40.3 11.3 0.005
Follow-up, mg/dl 48.1 15.9 43.8 12.6 0.001
Percent change 11.9 3.4 9.8 3.6 0.10
Triglycerides
Baseline, mg/dl 141.6 (101.0–201.0) 157.0 (100.1–216.0) 0.05
Follow-up, mg/dl 130.5 (96.0–177.7) 132.9 (97.9–191.0) 0.44
Percent change 6.5 3.3 6.8 4.0 0.88
C-reactive protein
Baseline, mg/l 2.6 (1.1–5.6) 3.8 (1.7–7.8) 0.001
Follow-up, mg/l 2.0 (1.0–4.4) 3.0 (1.4–6.8) 0.001
Percent change 20.3 4.8 7.0 8.1 0.02
Systolic blood pressure
Baseline, mm Hg 127.1 16.3 131.8 17.4 0.001
Follow-up, mm Hg 129.0 13.4 131.1 12.9 0.02
Percent change 2.2 0.6 2.4 0.8 0.76
Diastolic blood
pressure
Baseline, mm Hg 75.8 9.3 74.9 10.4 0.17
Follow-up, mm Hg 76.3 7.4 74.7 7.6 0.002
Percent change 1.6 0.4 0.2 0.7 0.02
Values are mean  SD or median (interquartile range).
PAD  peripheral arterial disease.
Measures of Atheroma Burden and Vessel WallDimensions in Patients With and Without PADTable 3 Measures of Atheroma Burd n and Vessel WallDimensions in Patients With and Without PAD
Parameter
Non-PAD
(n  3,263)
PAD
(n  216) p Value
Percent atheroma volume, % 38.5 9.1 40.4 9.2 0.002
Total atheroma volume, mm3 191.5 83.1 192.0 86.8 0.83
Lumen volume, mm3 301.4 110.3 275.7 101.6 0.001
Vessel volume, mm3 492.9 169.8 467.7 166.8 0.01
Remodeling index 0.95 0.19 0.94 0.19 0.76
Percent images with plaque 73.0 27.5 75.4 27.9 0.12
Percent images with calcium 30 (11.6–50.8) 34.7 (15.4–60.7) 0.002Values are mean  SD or median (interquartile range).
PAD  peripheral arterial disease.of the arterial segment imaged, there was no difference
between the groups with regard to the remodeling index at
the most diseased site (p  0.76).
Greater progression of both PAV (0.58  0.38%
vs. 0.23  0.3%, p  0.009) and TAV (0.17  2.69
mm3 vs. 2.05  2.15 mm3, p  0.03) was observed in
AD patients (Fig. 1). Patients with PAD were more likely
o undergo substantial progression (35.6% vs. 27.2%, p 
.007) and less likely to undergo regression (15.3% vs.
2.3%, p  0.02) (Fig. 1). Propensity matching patients
ith PAD (n  202) and without PAD (n  606)
emonstrated greater progression of PAV (0.54 
0.38% vs. 0.23  0.33%, p  0.03), but no difference in
change in TAV (0.36  2.63 mm3 vs. 1.73  2.24
mm3, p  0.20; c-statistic 0.74) (Table 4).
Intensive lipid lowering and disease progression. The
impact of intensive lipid lowering on disease progression in
patients with and without PAD is summarized in Figure 2.
Achieving levels of low-density lipoprotein cholesterol 70
mg/dl was associated with less progression of PAV (0.16 
0.27% vs. 0.76  0.20%, p  0.04; and 0.05  0.14%
vs.0.29 0.13%, p 0.001) and TAV (3.0 1.9 mm3
Clinical Characteristics ofPropensity-M tched PopulationTable 4 Clinical Charac eristics ofPropensity-Matched Population
Parameter
No PAD
(n  606)
PAD
(n  202) p Value
Age, yrs 60.8 9.1 60.9 8.9 0.94
Female 29.5 35.6 0.10
Race, Caucasian 91.7 88.1 0.37
Current smoker 31.7 32.5 0.85
Body mass index, kg/m2 31.6 5.9 31.7 5.9 0.91
Hypertension 83.5 84.2 0.83
Diabetes mellitus 40.4 40.1 0.93
Hyperlipidemia 84.5 84.2 0.91
Heart failure 5.9 5.9 1.00
History of myocardial infarction 33.5 31.2 0.55
Stroke 0.7 1.0 0.64
History of PCI 50.7 45.5 0.22
History of CABG 1.2 3.7 0.05
Baseline medication use
Statin 75.2 73.3 0.56
High-dose statin 20.8 30.1 0.05
Beta-blocker 74.6 73.3 0.71
Aspirin 93.1 90.6 0.25
ACE inhibitors 50.5 46.5 0.33
Calcium-channel blockers 37.0 36.1 0.83
Concomitant medications
Statin 94.2 91.6 0.19
High-dose statin 38.3 44.8 0.13
Beta-blockers 76.4 78.7 0.50
Aspirin 94.2 92.1 0.28
ACE inhibitors 57.3 55.0 0.57
Calcium-channel blockers 42.2 42.6 0.93
Values are mean  SD or %.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft surgery; PAD 
peripheral arterial disease; PCI  percutaneous coronary intervention.vs. 1.0  1.4 mm3, p  0.04; and 3.3  1.1 mm3 vs.
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PAD and Coronary Atherosclerosis March 8, 2011:1220–51.6  1.0 mm3, p  0.001) in patients with PAD and
ithout PAD, respectively. Similarly, achieving low-density
ipoprotein cholesterol levels70 mg/dl was associated with
lower frequency of progressors (24.6% vs. 39.6%, p 
.04; and 20.8% vs. 29.6%, p  0.001) and greater fre-
uency of regressors (26.3% vs. 11.3%, p  0.007; and
6.0% vs. 20.9%, p  0.002) in patients with PAD and
ithout PAD, respectively.
iscussion
he findings further support the clinical importance of PAD.
atients with PAD demonstrated more extensive and calcified
oronary atherosclerosis, impaired arterial remodeling, and
reater disease progression. Persistence of greater disease pro-
ression after propensity matching for cardiovascular risk
actors support findings from clinical cohorts (3,15) and sug-
est a potentially more aggressive systemic atherosclerosis in
AD patients. Despite the presence of more advanced disease,
AD patients retain the ability to derive a beneficial impact
rom use of intensive risk modification strategies.
The findings of smaller vessel wall volumes, despite a similar
AV, suggest a trend toward more constrictive remodeling of
he coronary arteries in PAD patients. That is likely to result in
ore luminal narrowing and a greater need for revasculariza-
ion. The impact of more calcified coronary atherosclerosis on
emodeling and subsequent propensity to plaque rupture re-
ain to be established. Nevertheless, the current findings
rovide further evidence to support the concept that athero-
clerosis is a systemic disorder involving multiple vascular
Figure 2 Intensive LDL-C Lowering and Disease Progression
Progression of (A) PAV and (B) TAV, and percentage of patients undergoing (C) pr
according to the presence or absence of PAD and achieved low-density lipoproteinerritories and that the presence of PAD is associated with a darticularly aggressive form of the disease. This supports
eports that accelerated disease progression of PAD is associ-
ted with more coronary events (16).
The factors underlying the relationship between acceler-
ted atherosclerosis progression and adverse outcomes re-
uire further exploration. Reports that CAD patients with
ymptoms of intermittent claudication have higher circulat-
ng levels of inflammatory and prothrombotic biomarkers
17) suggest that these pathways may play a role in accel-
rating the disease process. The potential impact of these
actors on disease burden and composition and its transla-
ion to ischemic events requires further investigation. The
ndings emphasize the need for greater adoption of risk-
odifying strategies by patients with PAD. The need is
empered by observations that PAD is frequently underdi-
gnosed and undertreated (5,18).
Several caveats should be noted with regard to the current
nalysis. The PAD was recorded by investigators on the basis
f an established clinical diagnosis, at the time of entry to the
tudies. As a result, it is possible that additional patients with
symptomatic PAD may have been missed. That does not
iminish the importance of the current observations of more
xtensive disease burden and progression in patients with an
stablished clinical diagnosis of PAD. The analysis involved a
ooling of data from 7 clinical trials. However, controlling for
tudy and use of mixed modeling in the statistical analysis and
easurement of all images in a central core laboratory provide
he opportunity to characterize the impact of PAD on disease
rogression in a large sample of subjects. The findings are
ion and (D) regression,
sterol (LDL-C) levels. Abbreviations as in Figure 1.ogress
choleerived from patients who present for a clinically indicated
1225JACC Vol. 57, No. 10, 2011 Hussein et al.
March 8, 2011:1220–5 PAD and Coronary Atherosclerosiscoronary angiogram. As a result, it is unknown whether the
observations can be translated to patients with asymptomatic
CAD. Although PAD patients demonstrated greater disease
progression and event rates, the association between progression of
coronary atherosclerosis on IVUS and clinical outcome requires
ongoing elucidation.
The current findings demonstrate that patients with CAD
and PAD harbor more extensive and calcified coronary ath-
erosclerosis, constrictive vascular remodeling, and accelerated
disease progression. These observations provide an important
mechanistic link to the adverse cardiovascular outcomes among
patients with PAD. The findings support the need for inten-
sification of medical therapies to achieve more effective reduc-
tions in cardiovascular risk.
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